Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349491 · ClinicalTrials.gov registry record · Phase 3
Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion
A Phase 3 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT01349491 is a Phase 3 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 10 participants.
The verdict
NCT01349491, a Phase 3 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators hypothesize that ranolazine would decrease the incidence of recurrence of Atrial Fibrillation (AF) after electrical cardioversion of persistent AF. Patients with persistent AF who are candidates for electrical cardioversion will be randomized to either placebo or ranolazine after successful electrical cardioversion.
Interventions
- DRUG Matching placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349491
The ClinicalTrials.gov registry entry for NCT01349491 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT01349491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349491 about?
NCT01349491 is a clinical study titled "Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion". The investigators hypothesize that ranolazine would decrease the incidence of recurrence of Atrial Fibrillation (AF) after electrical cardioversion of persistent AF. Patients with persistent AF who are candidates for electrical cardioversion will be randomized to either placebo or ranolazine after s...
What is the current status of trial NCT01349491?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2012-03. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01349491?
The interventions under investigation include: Matching placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01349491?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.